NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback